Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(20):1488-1489; doi:10.1093/jnci/dji360
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cengel, K. A.
Right arrow Articles by Glatstein, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cengel, K. A.
Right arrow Articles by Glatstein, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

EDITORIAL

C225 and PDT Combination Therapy for Ovarian Cancer: The Play's the Thing

Keith A. Cengel, Stephen M. Hahn, Eli Glatstein

Affiliation of authors: Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

Correspondence to: Eli Glatstein, MD, University of Pennsylvania, Abramson Cancer Center, Department of Radiation Oncology, 3400 Spruce St.–2 Donner Bldg., Philadelphia, PA 19104–4283 (e-mail: glatstein@xrt.upenn.edu).

The first 10% of the full text of this article appears below.

The prognosis for women diagnosed with advanced-stage epithelial ovarian cancer is poor, with fewer than one-third of patients surviving 5 years. Locally advanced pelvic tumors are often associated with diffuse peritoneal carcinomatosis and bulky tumor lesions involving the omentum, bowel, mesentery, and diaphragmatic surface. Even after aggressive cytoreductive surgery and platinum-based chemotherapy, most of these patients experience local progression or recurrence. The reasons for treatment failure probably relate to difficulties inherent to surgery within the peritoneal cavity, problems related to administering cytotoxic agents to the tumor cells in cytotoxic concentrations, and the ability of ovarian cancer cells to develop resistance to standard chemotherapies.

In this issue of the Journal, del Carmen and colleagues (1) present evidence that intraperitoneal administration of C225, a humanized murine monoclonal antibody directed against . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?